4th Quarter - Report
TODD STRATEGY GROUP for ALKERMES, INC.
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Prescription drug pricing. S.3799 - Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act. Awareness of outcomes data and the need for training on all medication assisted treatment. H.R.7667/S.4348 - Prescription Drug User Fee Agreement Reauthorization. H.R.5376 - Inflation Reduction Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL | — |
| JEFF LUCAS | — |
| DANIEL M TODD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.